- Datum15.01.2025
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalter
stock3
Thomas May
Moderator
Spruce Biosciences Inc. Registered Shares DL -,0001 Aktie
Verkaufen
Kaufen
Spruce Biosciences Inc. Registered Shares DL -,0001 Chart
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Spruce Biosciences Inc. Registered Shares DL -,0001 Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
4,53 %
Intraday
-2,26 %
1 Woche
-3,08 %
1 Monat
-11,57 %
Seit Jahresbeginn
-85,02 %
1 Jahr
-89,17 %
3 Jahre
Wikifolio
Passender Service zu Spruce Biosciences Inc. Registered Shares DL -,0001
Webinar zu Spruce Biosciences Inc. Registered Shares DL -,0001
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,342-5,950
- Jahrestief / Hoch ($)0,342-0,439
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Spruce Biosciences Inc. Registered Shares DL -,0001
Keine Dividenden verfügbar
Termine von Spruce Biosciences Inc. Registered Shares DL -,0001
Keine aktuellen Termine
Beschreibung
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
